Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 901-911

  Lucas, Pamela W ^a   Schmit, Joanna M ^a   Peterson, Quinn P ^c   West, Diana C ^a   Hsu, Danny C ^a   Novotny, Chris J ^c   Dirikolu, Levent ^a   Churchwell, Mona I ^b   Doerge, Daniel R ^b   Garrett, Laura D ^a   Hergenrother, Paul J ^a,c   Fan, Timothy M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Comparative and translational oncology; Non Hodgkin's lymphoma; Novel anticancer strategy; Pharmacokinetic modeling; Procaspase 3 activation

Indexed keywords

ANTINEOPLASTIC AGENT; DUAL SPECIFICITY PHOSPHATASE 2; PROCASPASE 3; (4 BENZYLPIPERAZIN 1 YL)ACETIC ACID (3 ALLYL 2 HYDROXYBENZYLIDENE)HYDRAZINE; (4-BENZYLPIPERAZIN-1-YL)ACETIC ACID (3-ALLYL-2-HYDROXYBENZYLIDENE)HYDRAZINE; CASPASE 3; CELL EXTRACT; ENZYME ACTIVATOR; HYDRAZONE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LOADING DRUG DOSE; LYMPHOMA CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; TREATMENT RESPONSE; ANIMAL; APOPTOSIS; DRUG EFFECT; HEALTH; METABOLISM; MOLECULAR LIBRARY; TIME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL EXTRACTS; CELL LINE, TUMOR; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ACTIVATORS; HEALTH; HUMANS; HYDRAZONES; PIPERAZINES; SMALL MOLECULE LIBRARIES; TIME FACTORS;

EID: 84855579688     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9445-z     Document Type: Article

References (37)

1. Li J, Yuan J (2008) Caspases in apoptosis and beyond. Oncogene 27:6194-6206
2. Mori C, Nakamura N, Kimura S, Irie H, Takigawa T et al (1995) Programmed cell death in the interdigital tissue of the fetal mouse limb is apoptosis with DNA fragmentation. Anat Rec 242:103-110
3. Takanosu M, Amasaki H, Iwama Y, Ogawa M, Hibi S et al (2002) Epithelial cell proliferation and apoptosis in the developing murine palatal rugae. Anat Histol Embryol 31:9-14
4. Arnold R, Brenner D, Becker M, Frey CR, Krammer PH (2006) How T lymphocytes switch between life and death. Eur J Immunol 36:1654-1658
5. Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P (2002) Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol 14:354-359
6. Medema JP, Borst J (1999) T cell signaling: a decision of life and death. Hum Immunol 60:403-411
7. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
8. Downward J (2004) PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15:177-182
9. Gurumurthy S, Vasudevan KM, Rangnekar VM (2001) Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 20:225-243
10. Pop C, Salvesen GS (2009) Human caspases: activation, specificity, and regulation. J Biol Chem 284:21777-21781
11. Fink D, Schlagbauer-Wadl H, Selzer E, Lucas T, Wolff K et al (2001) Elevated procaspase levels in human melanoma. Melanoma Res 11:385-393
12. Izban KF, Wrone-Smith T, Hsi ED, Schnitzer B, Quevedo ME et al (1999) Characterization of the interleukin-1betaconverting enzyme/ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease. Am J Pathol 154:1439-1447
13. Krepela E, Prochazka J, Liul X, Fiala P, Kinkor Z (2004) Increased expression of Apaf-1 and procaspase-3 and the functionality of intrinsic apoptosis apparatus in non-small cell lung carcinoma. Biol Chem 385:153-168
14. Nakagawara A, Nakamura Y, Ikeda H, Hiwasa T, Kuida K et al (1997) High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res 57:4578-4584
15. O'Donovan N, Crown J, Stunell H, Hill AD, McDermott E et al (2003) Caspase 3 in breast cancer. Clin Cancer Res 9:738-742
16. Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS et al (2006) Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2:543-550
17. Peterson QP, Goode DR, West DC, Ramsey KN, Lee JJ et al (2009) PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J Mol Biol 388:144-158
18. Peterson QP, Hsu DC, Goode DR, Novotny CJ, Totten RK et al (2009) Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3. J Med Chem 52:5721-5731
19. Dukers DF, Oudejans JJ, Vos W, ten Berge RL, Meijer CJ (2002) Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method. J Pathol 196:307-315
20. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
21. Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA et al (2005) Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 105:2916-2923
22. Gibaldi M, Perrier D (1982) Pharmacokinetics. 2nd edn. Dekker, New York, pp 409-447
23. Gibaldi M, Perrier D (1975) Pharmacokinetics. Dekker, New York, p 281
24. Martinez MN (1998) Use of pharmacokinetics in veterinary medicine. Article. II: Volume, clearance, and half-life. J Am Vet Med Assoc 213:1122-1127
25. Martinez MN (1998) Noncompartmental methods of drug characterization: statistical moment theory. J Am Vet Med Assoc 213:974-980
26. Shargel L, Yu A B C (1993) Applied biopharmaceuticals and pharmacokinetics, 3rd edn. Appleton and Lange Publishers, Norwalk
27. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS et al (1999) Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. Embo J 18:5242-5251
28. Hay BA, Wassarman DA, Rubin GM (1995) Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death. Cell 83:1253-1262
29. Kasof GM, Gomes BC (2001) Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 276:3238-3246
30. Lin JH, Deng G, Huang Q, Morser J (2000) KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun 279:820-831
31. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R (2001) X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and-7 in distinct modes. J Biol Chem 276:27058-27063
32. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P et al (2006) The dog as a cancer model. Nat Biotechnol 24:1065-1066
33. Hahn KA, Bravo L, Adams WH, Frazier DL (1994) Naturally occurring tumors in dogs as comparative models for cancer therapy research. In Vivo 8:133-143
34. Vail DM, MacEwen EG (2000) Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18:781-792
35. Coiffier B (2006) Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma 7(Suppl 1):S7-13
36. Rassnick KM, McEntee MC, Erb HN, Burke BP, Balkman CE et al (2007) Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma. J Vet Intern Med 21:1364-1373
37. Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8:147-156